Tag: Rapamycin Holdings

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO
28Feb By Iris GonzalezNo Comments
Articles, Featured

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

San Antonio-based Rapamycin Holdings, Inc. announced its rebranding Tuesday as Emtora Biosciences with Dr. Carole Spangler Vaughn as its new chief executive officer. Dan Hargrove recruited Spangler Vaughn as his replacement after hiring her as a consultant for the privately-held drug development company about six months ago.The drug company is commercializing a ground-breaking cancer prevention drug, eRapa™, a proprietary reformulation of the generic drug Rapamycin. The changes reflect the company's goal to get the drug through the regulatory approval process faster for a quicker market launch.“I’ve brought drugs to the market before,” Spangler Vaughn told Startups San Antonio. “With my background and experience, I can ask detailed questions about the science, then ask about the dr...
Read More
Rapamycin Holdings Treats First Humans in eRapa Clinical Trial
19Sep By Iris GonzalezNo Comments
Articles, Featured

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Rapamycin Holdings, Inc. (RHI), a privately-held drug development company, has started treating human patients with its proprietary formulation of a ground-breaking cancer prevention drug. The San Antonio-based company is commercializing eRapa, a novel reformulation of the generic drug Rapamycin. This first human Phase 1b clinical trial of eRapa will treat men with early-stage prostate cancer.Twelve to 24 qualified patients are in the first human trials to establish safety and the optimal dose of eRapa. Michael Liss, M.D., a urologic oncologist at UT Health San Antonio MD Anderson Cancer Center, is leading the clinical trial at the center where the Phase 1b study is being conducted. The cancer center has a long history of testing cancer breakthrough therapies in their early-phase cance...
Read More
SwRI Shares Pharmaceutical Expertise with New Workshop Oct. 8
28Aug By Iris GonzalezNo Comments
Articles, Featured

SwRI Shares Pharmaceutical Expertise with New Workshop Oct. 8

Southwest Research Institute (SwRI) is hosting a one-day workshop on Oct. 8 to teach life science professionals strategies and tools needed for a more successful investigational new drug (IND) submission. This workshop, to be held at SwRI, is designed for beginner- to intermediate-level bioscience professionals involved in new drug development.The workshop will help showcase SwRI’s specialized capabilities such as its new clean room, high-potency laboratory space, and complimentary storage facility to the bioscience community. The institute’s 2017 annual report details recent infrastructure investments and educational outreach efforts such as this inaugural workshop that can help attract more drug development to SwRI as well as benefit local startups bringing drugs to market.The Sm...
Read More